The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT)

ConclusionOur study indicates that the ALBI index more precisely predicted liver failure and survival in HCC following SBRT compared to CP scoring. Its application may help select the most ideal candidates for SBRT among the often heterogeneous CP-A population. Further study regarding precautionary measures such as functional treatment planning for ALBI-2 patients treated with liver SBRT may be warranted.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research